Improving Data Reliability Using a Non-Compliance Detection Method versus Using Pharmacokinetic Criteria

Data from clinical trials present numerous problems for the data analyst. These include non-compliance with the prescribed dosing regimen and inaccurate recollection of dosing history by patients as well as mistakes in recording data. Several methods have been proposed to address these issues. One such technique by Lu et  al. (Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J. Pharmacokinet. Pharmacodyn. 28:343–362 (2001)) identifies occasions in pharmacokinetic (PK) data where the preceding dosing history is likely to be unreliable. We used this method, implemented in the software program NONMEM (beta) VI, to clean a dataset containing indinavir (IDV) plasma concentrations from HIV-1 infected patients. The data was also cleaned by inspection in Microsoft Excel using clinical PK criteria. A one-compartment model with first order absorption and elimination was fit to both sets of cleaned data. IDV population PK parameters obtained from these analyses were similar to those reported previously. It is established that IDV nephrotoxicity is related to high IDV exposure. However, no relationships were found between any PK parameters and nephrotoxicity in the “compliance cleaned” dataset. In the “PK cleaned” dataset, the oral clearance and apparent volume were lower by 9.1% and 6.6%, respectively in patients with any type of nephrotoxicity and the maximum IDV concentration (Cmax) was 12.1% higher. In patients suffering from nephrolithiasis in particular, Cmax was 15.5% higher. Accordingly, the use of the non-compliance detection method did not improve the reliability of our dataset over the usual method of applying clinical criteria. In fact, analyses on the compliance-cleaned dataset missed some exposure-toxicity relationships. Thus, automated methods must be tested rigorously with ‘real life’ datasets, used with caution, and always in conjunction with clinical reasoning to avoid overlooking a signal in noisy data.

[1]  R M Schulz,et al.  Patient compliance—an overview , 1992, Journal of clinical pharmacy and therapeutics.

[2]  J. Steinberg,et al.  Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. , 1998, Archives of pathology & laboratory medicine.

[3]  L. Sheiner,et al.  Estimating treatment effect in the presence of non‐compliance measured with error: precision and robustness of data analysis methods , 2004, Statistics in medicine.

[4]  Marshall Joffe,et al.  Causal logistic models for non‐compliance under randomized treatment with univariate binary response , 2003, Statistics in medicine.

[5]  Hulin Wu,et al.  Comparison of Two Indinavir/Ritonavir Regimens in the Treatment of HIV-Infected Individuals , 2004, Journal of acquired immune deficiency syndromes.

[6]  T. Jarrett,et al.  Protease inhibitor-induced urolithiasis. , 1997, Urology.

[7]  S. Hammer,et al.  Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir , 2002, Clinical pharmacology and therapeutics.

[8]  K. Miller,et al.  Crystalluria and Urinary Tract Abnormalities Associated with Indinavir , 1997, Annals of Internal Medicine.

[9]  S. Hammer,et al.  A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. , 2003, The Journal of infectious diseases.

[10]  P. Reiss,et al.  Administration of Indinavir and Low-Dose Ritonavir (800/100 Mg Twice Daily) with Food Reduces Nephrotoxic Peak Plasma Levels of Indinavir , 2002, Antiviral therapy.

[11]  T. van der Poll,et al.  A Retrospective, Cohort‐Based Survey of Patients Using Twice‐Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and Efficacy , 2001, Journal of Acquired Immune Deficiency Syndromes.

[12]  J. Beijnen,et al.  The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. , 1999, AIDS.

[13]  Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. , 2001, The Journal of infectious diseases.

[14]  C. T. Viswanathan,et al.  Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1992, Clinical pharmacology and therapeutics.

[15]  J. Dieleman,et al.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. , 1999, AIDS.

[16]  W. Bennett,et al.  Renal toxicity of protease inhibitors , 2000, Current opinion in nephrology and hypertension.

[17]  C. Solas,et al.  High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. , 2002, Journal of acquired immune deficiency syndromes.

[18]  Mats O. Karlsson,et al.  Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  M. Karlsson,et al.  Discrimination Between Rival Dosing Histories , 1997, Pharmaceutical Research.

[20]  Peter L. Anderson,et al.  Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir , 2001, Antimicrobial Agents and Chemotherapy.

[21]  E. Saltel,et al.  Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. , 2000, The Journal of urology.

[22]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[23]  B Vrijens,et al.  The impact of compliance in pharmacokinetic studies , 1999, Statistical methods in medical research.

[24]  S. Hammer,et al.  Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398 , 2003, Antimicrobial Agents and Chemotherapy.

[25]  John Urquhart,et al.  Role of Patient Compliance in Clinical Pharmacokinetics , 1994 .

[26]  A. Telenti,et al.  Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus , 2004, Antimicrobial Agents and Chemotherapy.

[27]  N M Laird,et al.  Correcting for non-compliance in randomized trials: an application to the ATBC Study. , 1999, Statistics in medicine.

[28]  J. Miro,et al.  Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  B. G. Blijenberg,et al.  Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored Cohort of HIV-Infected Patients Treated with Indinavir , 2003, Journal of acquired immune deficiency syndromes.

[30]  Thomas M. Ludden,et al.  Estimation of Population Pharmacokinetic Parameters in the Presence of Non-compliance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  L. Sheiner,et al.  Selecting Reliable Pharmacokinetic Data for Explanatory Analyses of Clinical Trials in the Presence of Possible Noncompliance , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  K. Miller,et al.  Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Tosiya Sato A method for the analysis of repeated binary outcomes in randomized clinical trials with non‐compliance , 2001, Statistics in medicine.

[34]  W. H. Porter,et al.  Urolithiasis associated with the protease inhibitor indinavir. , 1997, Urology.

[35]  D. Richman,et al.  Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine , 2003, AIDS.

[36]  M. Resnick,et al.  Protease inhibitors and urolithiasis. , 1997, The Journal of urology.

[37]  J. Wade,et al.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  L. Sheiner,et al.  Population one‐compartment pharmacokinetic analysis with missing dosage data , 2004, Clinical pharmacology and therapeutics.

[39]  Scott A. Sisson,et al.  Transdimensional Markov Chains , 2005 .

[40]  E. Acosta,et al.  Indinavir Concentrations and Antiviral Effect , 1999, Pharmacotherapy.

[41]  B. Stricker,et al.  Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort. , 2002, Archives of internal medicine.

[42]  L B Sheiner,et al.  A Markov mixed effect regression model for drug compliance. , 1998, Statistics in medicine.

[43]  M. Rowland,et al.  Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies , 2004, European Journal of Clinical Pharmacology.

[44]  C. Tsoukas,et al.  Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  D. Richman,et al.  Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients , 2000, AIDS.